Compounded vs Brand-Name GLP-1s: What Actually Changed in 2026

A compounded GLP-1 is a version of semaglutide or tirzepatide mixed by a licensed compounding pharmacy rather than manufactured by Novo Nordisk or Eli Lilly. It contains the same active molecule, but it is not the same product — and critically, it is not FDA-approved.

Compounding is a long-standing, legitimate part of American pharmacy. It exists so pharmacists can make a medication a specific patient needs when the commercial version will not work: a liquid version for someone who cannot swallow pills, a preservative-free version for someone with an allergy, a dose strength that is not commercially made. There are two categories of compounder. 503A pharmacies make patient-specific preparations against an individual prescription — these are the ones telehealth weight-loss platforms use. 503B outsourcing facilities produce larger batches under stricter federal oversight.

What happened between 2022 and 2024 was unusual. Demand for GLP-1s exploded, the FDA placed both drugs on its official shortage list, and federal law permits compounding of drugs that are in shortage. That opened a window in which compounding pharmacies could legally produce what were, functionally, copies of Wegovy and Zepbound. An entire telehealth industry grew inside that window, often at $150–$300 a month when brand-name products carried list prices above $1,000.

That window is now closed. Understanding what replaced it is the difference between an informed decision and an expensive surprise. If you are weighing your options, it is also worth reading our overview of [how to get a GLP-1 prescription online in 2026](/blog/glp1-telehealth-providers-how-to-get-a-prescription-online-2026), which covers the provider landscape more broadly.

Yes, but under much narrower conditions than in 2024. Compounding a drug simply because it is cheaper than the brand is not one of them.

Here is the regulatory timeline that matters. The FDA declared the tirzepatide shortage resolved in October 2024, with enforcement discretion for 503A pharmacies ending February 18, 2025 and for 503B facilities on March 19, 2025. The semaglutide shortage was declared resolved on February 21, 2025, with a parallel wind-down. Once a drug is off the shortage list, the shortage-based justification for compounding a copy disappears.

What remains legal is genuine patient-specific compounding. Federal law prohibits compounding a drug that is "essentially a copy" of a commercially available product — but it permits compounding when a prescriber documents that a specific patient needs something the commercial product does not offer. In practice that means a documented allergy or intolerance to an inactive ingredient in the brand product, or a clinically justified dose or formulation the commercial pen does not provide. The documentation has to be real and individualized, in the patient's chart.

The direction of travel got clearer in April 2026, when the FDA proposed removing semaglutide and tirzepatide from the 503B bulk drug substances list, issued roughly 30 warning letters to compounding operations, and opened a public comment period. That is a proposal rather than a finalized ban, and it applies to 503B outsourcing facilities rather than the 503A pharmacies most telehealth platforms use. But the signal is unambiguous.

What this means for you practically: if a platform is offering you compounded semaglutide with no clinical conversation about *why* you specifically need a compounded version, that is a flag worth noticing.

The price gap that made compounding compelling has narrowed dramatically. For many people the brand-name product is now within a few dollars of the compounded one — and occasionally cheaper.

Brand, paying cash through manufacturer direct programs:

• •Zepbound (tirzepatide) via LillyDirect: roughly $299/month for the 2.5 mg starter dose, $399 for 5 mg, and about $449 for maintenance doses from 7.5 mg through 15 mg when refilled within the program's window.
• •Wegovy (semaglutide) via NovoCare Pharmacy: injectable pens from about $149 to $299/month depending on dose. The oral semaglutide tablet runs about $149/month at the lower strengths and $299/month at 9 mg and 25 mg.

Compounded, through a telehealth platform: typically $150–$400/month, often bundled with provider visits and shipping. Prices rose across 2025 as legal risk increased and supply of active pharmaceutical ingredient tightened.

With insurance: if your plan covers a GLP-1 for weight management, your copay may land anywhere from $25 to $100 a month, which beats every cash option. Coverage remains inconsistent and frequently requires prior authorization — if you have been turned down, our guide on [appealing a GLP-1 insurance denial](/blog/glp1-insurance-denial-how-to-appeal-prior-authorization-2026) walks through the process. Medicare rules are their own separate maze, covered in [does Medicare cover GLP-1 weight loss drugs](/blog/does-medicare-cover-glp1-weight-loss-drugs-2026).

The honest summary: in 2023, compounding could save you $800 a month. In 2026 it might save you $50 — or nothing. That changes the risk calculation entirely, because you are no longer trading safety oversight for a life-changing amount of money.

Compounded GLP-1s occupy a genuine grey zone: many people use them without incident, and the FDA has documented real harms. The core issue is that quality varies enormously between pharmacies and you have no straightforward way to verify it.

What the FDA has specifically warned about:

Dosing errors. Compounded products often arrive in vials with syringes rather than pre-calibrated pens. The FDA has received reports of patients drawing up five to twenty times the intended dose because of unit confusion between milligrams, milliliters and "units." Several required hospitalization. A pen doses itself; a vial and syringe rely on you getting the arithmetic right, every week, sometimes while nauseated.

Salt forms. Some compounders have used semaglutide sodium or semaglutide acetate rather than the semaglutide base in the approved products. These are different chemical entities. They have not been through the clinical trials, and the FDA has explicitly stated they are not the same active ingredient.

Sourcing. Active pharmaceutical ingredient for compounded GLP-1s frequently originates from overseas suppliers, some of which are not FDA-registered. Independent testing of compounded samples has repeatedly found potency outside the labeled range in both directions.

No adverse event infrastructure. When a brand drug causes a problem, it flows into a national reporting system that can trigger label changes. Compounded products lack that surveillance almost entirely.

None of this means every compounded GLP-1 is dangerous. Reputable 503A pharmacies with third-party potency testing exist, and plenty of people have used them successfully. But "probably fine" is a different standard than "verified by regulators," and it is worth being clear-eyed about which one you are choosing.

Work through cost, safety and continuity in that order — and start by checking whether the brand option is genuinely out of reach, because in 2026 it often is not.

Step 1: Check insurance first, properly. Call the number on your card and ask specifically whether the plan covers GLP-1s for weight management, what prior authorization requires, and whether there is a preferred agent. Plenty of people assume they are not covered without ever confirming it.

Step 2: Price the manufacturer direct programs. LillyDirect and NovoCare have changed the math substantially. If you are choosing compounded to save $40 a month, that is a much weaker argument than it was two years ago.

Step 3: If compounded is genuinely your only route, vet the pharmacy. Ask directly: Is this a 503A or 503B facility? Which state board licenses it, and can I see the license? Do you use semaglutide base, or a salt form? Do you third-party test each batch for potency, and will you share results? Is the product supplied in a pre-filled, calibrated pen or a vial? A pharmacy that answers these easily is a different proposition from one that deflects.

Step 4: Think about continuity. Regulatory pressure is increasing, not decreasing. If your supply depends on a compounding channel that may not exist in twelve months, you need a plan for what happens when it stops — because coming off a GLP-1 abruptly tends to bring appetite and weight back fast, as covered in our piece on [avoiding weight regain when you stop](/blog/stopping-glp1-in-menopause-how-to-avoid-weight-regain).

Step 5: Loop in a real prescriber. Whichever route you take, this should be a medical decision with monitoring — not a subscription. If you are still deciding between formats at all, our [oral vs injectable GLP-1 comparison](/blog/oral-vs-injectable-glp1-which-is-right-for-you) is a useful companion read.